- Home
- UPST vs IONS Comparison
UPST vs IONS Comparison
Compare UPST & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- IONS
- Stock Information
- Founded
- UPST 2012
- IONS 1989
- Country
- UPST United States
- IONS United States
- Employees
- UPST N/A
- IONS N/A
- Industry
- UPST Finance: Consumer Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- IONS Health Care
- Exchange
- UPST Nasdaq
- IONS Nasdaq
- Market Cap
- UPST 6.6B
- IONS 6.0B
- IPO Year
- UPST 2020
- IONS 1991
- Fundamental
- Price
- UPST $46.00
- IONS $27.26
- Analyst Decision
- UPST Buy
- IONS Buy
- Analyst Count
- UPST 14
- IONS 19
- Target Price
- UPST $77.08
- IONS $59.24
- AVG Volume (30 Days)
- UPST 4.7M
- IONS 1.6M
- Earning Date
- UPST 05-06-2025
- IONS 05-06-2025
- Dividend Yield
- UPST N/A
- IONS N/A
- EPS Growth
- UPST N/A
- IONS N/A
- EPS
- UPST N/A
- IONS N/A
- Revenue
- UPST $676,961,000.00
- IONS $705,138,000.00
- Revenue This Year
- UPST $50.82
- IONS N/A
- Revenue Next Year
- UPST $22.62
- IONS $25.71
- P/E Ratio
- UPST N/A
- IONS N/A
- Revenue Growth
- UPST 23.43
- IONS N/A
- 52 Week Low
- UPST $20.60
- IONS $27.20
- 52 Week High
- UPST $96.43
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- UPST 36.09
- IONS 27.86
- Support Level
- UPST $43.24
- IONS $31.04
- Resistance Level
- UPST $56.10
- IONS $33.76
- Average True Range (ATR)
- UPST 3.06
- IONS 1.28
- MACD
- UPST 0.11
- IONS -0.52
- Stochastic Oscillator
- UPST 21.48
- IONS 0.86
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.